Top in endocrinology: Testosterone therapy, bempedoic acid show promise
Click Here to Manage Email Alerts
According to findings from a recent study, men with type 2 diabetes and hypogonadism who received testosterone therapy experienced a sustained remission of their diabetes.
Another top story was about an analysis of four phase 3 trials that showed bempedoic acid significantly reduced LDL compared with placebo in patients with diabetes.
Read these and more top stories below.
Testosterone therapy associated with type 2 diabetes remission in men with hypogonadism
One-third of a cohort of men with type 2 diabetes and hypogonadism who received testosterone undecanoate therapy experienced a sustained remission of their diabetes, according to findings from a single-center study. Read more.
Bempedoic acid lowers LDL regardless of glycemic status
Researchers found that bempedoic acid significantly reduced LDL compared with placebo in patients with diabetes, prediabetes or normoglycemia and hypercholesterolemia. Read more.
Guidance for pituitary disease management during COVID-19
The COVID-19 pandemic presents substantial challenges for pituitary disease management, and clinicians should consider local conditions and hospital resources when opting for surgery vs. medical management, according to new guidance. Read more.
ASMBS: Bariatric surgery ‘medically necessary’ during COVID-19 pandemic
Bariatric surgery can improve obesity and the related diseases that increase risks for worse COVID-19 outcomes and should not be considered an elective procedure, according to the American Society for Metabolic and Bariatric Surgery. Read more.
Novel genetic data reveal two distinct PCOS subtypes
Researchers have identified two distinct subtypes of polycystic ovary syndrome associated with novel gene regions, a discovery that could improve disease diagnosis and potentially provide new pathways for drug targets. Read more.